All In Biotech

Drug Trial Radar · NCT05411588

A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE INTRAVENOUS AND SUBCUTANEOUS DOSES OF PF-07275315 IN HEALTHY PARTICIPANTS

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

65

Actual

Start

Jun 9, 2022

Primary completion

May 13, 2024

Study completion May 13, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) in healthy participants. This study is seeking participants who: * Are healthy as determined by medical evaluation. * Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * Have a body mass index (BMI) of 17.5 to 32 kilogram per meter square - a total body weight of more than 50 kilograms (110 pounds) Participants will be divided randomly into 8 different groups. All participants will receive either one PF-07275315 or a harmless treatment that has no medical effect (placebo) intravenous (IV) infusion (given directly into a vein). Participants will take part in this study for up to 541 days. During this time, eligible participants will receive single increasing amounts of PF-07275315 or placebo. Increase will only occur if the sponsor agrees that the next dose is likely to have acceptable safety and tolerability. The follow-up visit will take place 271 days after first treatment.

Conditions

  • Healthy Volunteers

Interventions

  • PF-07275315Drug

    Active drug

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs)Time frame: Baseline through study completion, approximately 561 days
  2. Number of participants with clinically meaningful change from baseline in laboratory Tests ResultsTime frame: Baseline through study completion, approximately 561 days
  3. Number of participants with clinically meaningful change from baseline in vital signsTime frame: Baseline through study completion, approximately 561 days
  4. Number of participants with Serious AEs (SAEs)Time frame: Baseline through study completion, approximately 561 days
  5. Number of participants with clinically meaningful change from baseline in ECG parametersTime frame: Baseline through study completion, approximately 561 days

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Orange County Research Center

    Lake Forest, California

  • Orange County Research Center

    Tustin, California

  • New Haven Clinical Research Unit

    New Haven, Connecticut

  • Qps-Mra, Llc

    South Miami, Florida

  • Pfizer Clinical Research Unit - Brussels

    Brussels, Bruxelles-capitale, Région de, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.